Phentermine Contraindication in Uncontrolled Hypertension

Contraindication and Rationale

Phentermine must be immediately discontinued in any patient whose blood pressure is not adequately controlled; the FDA and major medical guidelines list uncontrolled hypertension as an absolute contraindication. 1
As a sympathomimetic amine, phentermine raises heart rate and blood pressure by increasing central norepinephrine levels, creating a direct cardiovascular risk in patients with uncontrolled hypertension. 2

In patients with controlled hypertension, phentermine‑topiramate extended‑release produced modest reductions in blood pressure (≈ 4.7–5.6 mm Hg systolic and 3.4–3.8 mm Hg diastolic). These benefits were observed only when baseline hypertension was already controlled. 3
Large randomized trials that enrolled participants with baseline systolic blood pressure 140–160 mm Hg (130–160 mm Hg in those with diabetes) reported favorable blood‑pressure outcomes with phentermine‑topiramate when hypertension was controlled. 4

Semaglutide (2.4 mg weekly) or liraglutide (3.0 mg daily) are recommended as the safest and most effective weight‑loss alternatives for patients with cardiovascular risk; they have demonstrated cardiovascular benefit and lack sympathomimetic activity. 1
Dosing titration: semaglutide starts at 0.25 mg weekly and is increased to 2.4 mg over 16 weeks; liraglutide starts at 0.6 mg daily and is escalated to 3.0 mg over 4 weeks. 3
These agents stimulate insulin secretion in a glucose‑dependent manner, resulting in a very low risk of hypoglycemia; caution is advised when combined with insulin or sulfonylureas. 3

Orlistat reduces dietary fat absorption by inhibiting gastrointestinal lipases, blocking roughly 30 % of ingested fat; it is available as prescription (120 mg) and over‑the‑counter (60 mg) formulations. 1
Expected weight loss with orlistat is modest (pooled mean ≈ 2.6 kg at 6 months and ≈ 2.9 kg at 12 months). 1

All pharmacologic strategies should be combined with lifestyle interventions, including a reduced‑calorie diet and increased physical activity. 4

First choice: GLP‑1 receptor agonist (semaglutide or liraglutide) for superior efficacy and cardiovascular safety. 1
Second choice: Orlistat if GLP‑1 agents are contraindicated or not tolerated. 1

The historic “fen‑phen” combination caused valvular heart disease and pulmonary hypertension due to fenfluramine, not phentermine; this historical issue does not alter the current contraindication of phentermine in uncontrolled hypertension. 5
Continuing phentermine to achieve weight‑loss‑mediated BP reduction is unsafe; the sympathomimetic effects pose an immediate cardiovascular threat that outweighs any potential future benefit. 2
Re‑initiation of phentermine must be preceded by a repeat cardiovascular assessment to confirm that blood pressure is now controlled. 1